ReviewClinical cancer research : an official journal of the American Association for Cancer Research2013
Lessons learned from radiation oncology clinical trials.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Characteristics and innovative points of clinical trials of radiotherapy combined with immune checkpoint inhibitors in NSCLC over the past decade.Frontiers in medicine · 2025Pooled it
- Challenges and Opportunities in Developing an Oncology Clinical Trial Network in the United States Veterans Affairs Health Care System: The VA STARPORT Experience.Current oncology (Toronto, Ont.) · 2024Article
- Dosimetric validation of SmART-RAD Monte Carlo modelling for x-ray cabinet radiobiology irradiators.Physics in medicine and biology · 2024Article
- A scoping review of small animal image-guided radiotherapy research: Advances, impact and future opportunities in translational radiobiology.Clinical and translational radiation oncology · 2022Article
- Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies.Journal of the National Cancer Institute · 2021Review
- Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors.Biomaterials · 2020Article
- Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.Molecular cancer therapeutics · 2020Article
- A sparse orthogonal collimator for small animal intensity-modulated radiation therapy part I: Planning system development and commissioning.Medical physics · 2019Article
- Radiation treatment planning with embedded dose escalation.Radiation oncology (London, England) · 2019Article
- A novel data management platform to improve image-guided precision preclinical biological research.The British journal of radiology · 2019Article
- Integrating Small Animal Irradiators withFunctional Imaging for Advanced Preclinical Radiotherapy Research.Cancers · 2019Review
- Tumour and normal tissue radiobiology in mouse models: how close are mice to mini-humans?The British journal of radiology · 2017Review
- Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.Nature communications · 2016Article
- Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Review
- Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations.Translational oncology · 2016Review
- Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery.Cancer research · 2015Article
- Small animal image-guided radiotherapy: status, considerations and potential for translational impact.The British journal of radiology · 2015Review
- Enhancing the efficacy of radiation therapy: premises, promises, and practicality.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Article
- Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy.Journal of thoracic disease · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
A workshop entitled "Lessons Learned from Radiation Oncology Trials" was held on December 7-8, 2011, in Bethesda, MD, to present and discuss some of the recently conducted radiation oncology clinical trials with a focus on those that failed to refute the null hypothesis. The objectives of this workshop were to summarize and examine the questions that these trials provoked, to assess the quality and limitations of the preclinical data that supported the hypotheses underlying these trials, and to consider possible solutions to these challenges for the design of future clinical trials. Several themes emerged from the discussions: (i) opportunities to learn from null-hypothesis trials through tissue and imaging studies; (ii) value of preclinical data supporting the design of combinatorial therapies; (iii) significance of validated biomarkers; (iv) necessity of quality assurance in radiotherapy delivery; (v) conduct of sufficiently powered studies to address the central hypotheses; and (vi) importance of publishing results of the trials regardless of the outcome. The fact that well-designed hypothesis-driven clinical trials produce null or negative results is expected given the limitations of trial design and complexities of cancer biology. It is important to understand the reasons underlying such null results, however, to effectively merge the technologic innovations with the rapidly evolving biology for maximal patient benefit through the design of future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.